NLTX News and Press, Neoleukin Therapeutics Inc. From 08/06/20

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that management will participate in...

SEATTLE, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced it will report second quarter 2020 f...

Less than a year ago, Wall Street thought little of Neoleukin Therapeutics (NASDAQ: NLTX) . The drug developer was valued at less than $80 million and had yet to advance a pipeline asset into clinical trials. But that has changed. Shares of Neoleukin Therapeutics erupted in late 2019 and thr...

Three of the best-performing pharmaceutical stocks over the past year have been clinical-stage biotech and biopharmaceutical companies -- businesses that aren't making profits but have promising drugs, or more often, drug candidates. Though a few candidates will become breakout successes, the o...

Shares of Neoleukin Therapeutics (NASDAQ: NLTX) fell nearly 18% today after the company announced the pricing of a public offering of common stock and a separate offering of warrants to purchase common stock. The development-stage drug developer agreed to sell up to 5.75 million shares of co...

Neoleukin Therapeutics ( NLTX -14.5% ) has priced its public offering of 3,262,471 common shares at $15.25/share. More news on: Neoleukin Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

SEATTLE, July 02, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced the pricing of an underwritten pu...

Gainers:  VERO +53.3% . IO +44.8% . FEIM +36.8% . FRAN +12.2% . NUS +11.7% . More news on: Venus Concept Inc., ION Geophysical Corporation, Frequency Electronics, Inc., Stocks on the move, , Read more ...

SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that it intends to offer and sell,...

- NL-201 demonstrates durable antitumor activity in animal tumor models - - NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo - - Conditional activation of de novo proteins using split molecule technology may increase therapeutic index - - Company t...